Stella Ngozi Igwala, in Algona, WA - Registered Nurse

Stella Ngozi Igwala, is a Registered Nurse based in Algona, Washington. Stella Ngozi Igwala is licensed to practice in Washington (license number RN00144194) and her current practice location is 213 Junction Blvd, Algona, Washington. She can be reached at her office (for appointments etc.) via phone at (206) 240-5415.

NPI number for Stella Ngozi Igwala is 1104316447 and her current mailing address is 213 Junction Blvd, Algona, Washington. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1104316447.

Contact Information

	Stella Ngozi Igwala,
	213 Junction Blvd, Algona, WA 98001
	(206) 240-5415
	(253) 590-0091

Provider's Profile

Full Name	Stella Ngozi Igwala
Gender	Female
Speciality	Registered Nurse
Location	213 Junction Blvd, Algona, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1104316447
Provider Enumeration Date: 05/11/2018
Last Update Date: 06/25/2018

Medical Identifiers

Medical identifiers for Stella Ngozi Igwala such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1104316447	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
163W00000X	Registered Nurse	RN00144194 (Washington)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Stella Ngozi Igwala is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Stella Ngozi Igwala, 213 Junction Blvd, Algona, WA 98001-4436 Ph: (206) 240-5415	Stella Ngozi Igwala, 213 Junction Blvd, Algona, WA 98001 Ph: (206) 240-5415

News Archive

Dainippon Sumitomo Pharma acquires Sepracor

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") and Sepracor Inc. today announce the successful completion of DSP's acquisition of Sepracor for US$23.00 per share in cash. DSP completed the acquisition through a cash tender offer and by exercising an option to acquire additional shares directly from Sepracor followed by a short-form merger of an indirect wholly-owned subsidiary of DSP with and into Sepracor on October 20, 2009. Sepracor is now an indirect wholly-owned subsidiary of DSP.

Salk researchers develop new glioblastoma model using gene-edited organoids

Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.

Dengue and other viruses may have developed tricks that let them reproduce inside macrophages

A monoclonal antibody that can effectively treat mice infected with West Nile virus has an intriguing secret: Contrary to scientists' expectations, it does not block the virus's ability to attach to host cells. Instead, the antibody somehow stops the infectious process at a later point.

NCC, BD to implement cervical cancer early detection program for underserved women in Peru

The National Cancer Coalition and BD (Becton, Dickinson and Company), a leading global medical technology company, are pleased to announce the implementation of a cervical cancer early detection program to benefit 75,000 underserved women in Peru. With a goal to reduce the high cervical cancer mortality levels in the mountainous region surrounding Cusco, this extensive three-year program is set to conduct liquid-based cytology exams utilizing the BD SurePath™ Liquid-based Pap Test System.

Stella Ngozi Igwala, - Registered Nurse in Algona, WA